(Q44847730)

6 December 2017

title

Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance (English)

1 reference

6 December 2017

0 references

1 reference

1 reference

Bennett SM

1

1 reference

6 December 2017

Agrawal A

2

1 reference

6 December 2017

Elasha H

3

1 reference

6 December 2017

Heise M

4

1 reference

6 December 2017

Jones NP

5

1 reference

6 December 2017

Walker M

6

1 reference

6 December 2017

Wilding JP

7

1 reference

6 December 2017

publication date

1 May 2004

1 reference

6 December 2017

1 reference

6 December 2017

volume

21

1 reference

6 December 2017

issue

5

1 reference

6 December 2017

page(s)

415-422

1 reference

Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01155.X

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01155.X

Thiazolidinediones: metabolic actions in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01155.X

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01155.X

The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01155.X

Free fatty acids inhibit the glucose-stimulated increase of intramuscular glucose-6-phosphate concentration in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01155.X

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01155.X

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01155.X

Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01155.X

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01155.X

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01155.X

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-5491.2004.01155.X

10.1111/J.1464-5491.2004.01155.X

21 January 2018

Identifiers

DOI

1 reference

6 December 2017

1 reference